Pathogenesis, clinical and laboratory aspects of thrombosis in cancer

Journal of Thrombosis and Thrombolysis

Volumn 24, Issue 1, 2007, Pages 29-38

  Franchini, Massimo ^a   Montagnana, Martina ^b   Targher, Giovanni ^b   Manzato, Franco ^c   Lippi, Giuseppe ^b  

^a OSPEDALE POLICLINICO   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c CARLO POMA HOSPITAL   (Italy)

Author keywords

Anticoagulant; Cancer; Therapy; Thrombosis; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN; ANTIVITAMIN K; ASPARAGINASE; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CANCER PROCOAGULANT; D DIMER; DALTEPARIN; ENOXAPARIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; TAMOXIFEN; THROMBIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSACTIVATOR PROTEIN; VON WILLEBRAND FACTOR; WARFARIN;

ACUTE LEUKEMIA; BLEEDING; BLOOD CLOTTING; BLOOD FLOW; BREAST CANCER; CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CANCER RISK; CANCER SCREENING; CATHETER THROMBOSIS; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL FEATURE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; ENDOTHELIAL DYSFUNCTION; EPIGENETICS; FEEDBACK SYSTEM; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; HYPOXIA; INFLAMMATION; LABORATORY TEST; LOW DRUG DOSE; LUNG EMBOLISM; LYMPH NODE METASTASIS; OCCULT CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOEMBOLISM; THROMBOGENICITY; THROMBOSIS; TUMOR LYSIS SYNDROME; TUMOR VASCULARIZATION; TUMOR VOLUME; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS; VENOUS STASIS; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION; BLOOD FLOW VELOCITY; BLOOD VESSELS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOEMBOLISM; THROMBOPLASTIN; THROMBOSIS;

EID: 34249660457     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0028-6     Document Type: Review

References (99)

1. Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P (2006) Cancer and venous thromboembolism. Semin Thromb Hemost 32:694-699
2. Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6:401-410
3. Rak J, Yu JL, Luyendyk J, Mackman N (2006) Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 66:10643-10646
4. Garcia-Avello A, Galindo-Alvarez J, Martinez-Molina E, Cesar-Perez J, Navarro JL (2001) Coagulative system activation and fibrinolytic system inhibition activities arise from tumoral draining vein in colon carcinoma. Thromb Res 104:421-425
5. Falanga A, Marchetti M, Vignoli A, Balducci D (2003) Clotting mechanisms and cancer: Implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol 1:673-678
6. Chung I, Lip GY (2003) Virchow's triad revisited: Blood constituents. Pathophysiol Haemost Thromb 33:449-454
7. Falanga A, Rickles FR (1999) Pathophysiology of the thrombophilic state in the cancer patient. Sem Thromb Hemost 25:173-182
8. Maly MA, Tomasov P, Hajek P et al (2006) The role of tissue factor in thrombosis and haemostasis. Physiol Res (Nov 6, Epub ahead of print)
9. Versteeg HH (2004) Tissue factor as an evolutionary conserved cytokine receptor: Implications for inflammation and signal transduction. Semin Hematol 41:168-172
10. Mackman N (2006) Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis 36:104-107
11. Eilertsen KE, Osterud B (2004) Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 15:521-538
12. Zillmann A, Luther T, Muller I et al (2001) Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 281:603-609
13. Sturk-Maquelin KN, Nieuwland R, Romijn FP, Eijsman L, Hack CE, Sturk A (2003) Pro- and non-coagulant forms of non-cell-bound tissue factor in vivo. J Thromb Haemost 1:1920-1926
14. Lopez JA, Kearon C, Lee AY (2004) Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 439-456
15. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y (2003) Alternatively spliced human tissue factor: A circulating, soluble, thrombogenic protein. Nat Med 9:458-462
16. Chu AJ (2006) Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications. Cell Biochem Funct 24:173-192
17. Rak J, Milsom C, May L, Klement P, Yu J (2006) Tissue factor in cancer and angiogenesis: The molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 32:54-70
18. Babiker AA, Nilsson Ekdahl K, Nilsson B, Ronquist G (2007) Prothrombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma. Semin Thromb Hemost 33:80-86
19. Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, Lopez JA (2007) Microvesicle-associated tissue factor and Trousseau's syndrome. J Thromb Haemost 5:70-74
20. Rauch U, Antoniak S (2007) Tissue factor-positive microparticles in blood associated with coagulopathy in cancer. Thromb Haemost 97:9-10
21. Uno K, Homma S, Satoh T et al (2007) Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 96:290-295
22. Nierodzik ML, Karpatkin S (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10:355-362
23. Goodsell DS (2006) The molecular perspective: Tissue factor. Oncologist 11:849-850
24. Lopez-Pedrera C, Barbarroja N, Dorado G, Siendones E, Velasco F (2006) Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia 20:1331-1340
25. Pendurthi UR, Rao LV (2002) Factor VIIa/tissue factor-induced signaling: a link between clotting and disease. Vitam Horm 64:323-355
26. Semin Ruf W, Mueller BM (2006) Thrombin generation and the pathogenesis of cancer. Thromb Hemost 32(Suppl 1):61-68
27. Nierodzik ML, Karpatkin S (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10:355-362
28. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE (1997) Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3:1222-1227
29. Mueller BM, Reisfeld RA, Edgington TS, Ruf W (1992) Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 89:11832-11836
30. Heinrich JE, Pollard M, Wolter WA et al (2006) Vaccination against prostate cancer using a live tissue factor deficient cell line in Lobund-Wistar rats. Cancer Immunol Immunother (Epub ahead of print, Sep 5)
31. Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ (2004) Tissue factor and cancer metastasis: The role of intracellular and extracellular signaling pathways. Mol Med 10:6-11
32. Jiang X, Guo YL, Bromberg ME (2006) Formation of tissue factor-factor VIIa-factor Xa complex prevents apoptosis in human breast cancer cells. Thromb Haemost 96:196-201
33. De Cicco M (2004) The prothrombotic state in cancer: Pathogenic mechanisms. Crit Rev Oncol Hematol 50:187-196
34. Kwaan HC, Parmar S, Wang J (2003) Pathogenesis of increased risk of thrombosis in cancer. Semin Thromb Hemost 29:283-290
35. Gordon SG, Cross BA (1990) An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as new tumor marker. Cancer Res 50:6229-6243
36. Lee AY (2002) Cancer and thromboembolic disease: Pathogenic mechanisms. Cancer Treat Rev 28:137-140
37. Gale AJ, Gordon S (2001) Update on tumor cell procoagulant factors. Acta Haematol 106:25-32
38. Kamocka M, Rozalski M, Krajewska U, Wierzbicki R, Mielicki WP (2005) Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro. Cancer Lett 222:89-94
39. Nierodzik ML, Karpatkin S (2006) Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 10:355-362
40. Sampson MT, Kakkar AK (2002) Coagulation proteases and human cancer. Biochem Soc Trans 30:201-207
41. Bono F, Schaeffer P, Herault JP et al (2000) Arterioscler Thromb Vasc Biol 20:E107-E112
42. Riewald M, Kravchenko VV, Petrovan RJ, O'Brien PJ, Brass LF, Ulevitch RJ, Ruf W (2001) Blood 97:3109-3116
43. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R (2001) Proteinase-activated receptors. Pharmacol Rev 53:245-282
44. Rak J, Klement P, Yu J (2006) Genetic determinants of cancer coagulopathy, angiogenesis and disease progression. Vnitr Lek 52(Suppl 1):135-138
45. Smorenburg SM, Van Noorden CJ (2001) The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53:93-105
46. Dubina MV, Petrishchev NN, Anisimov VN (1999) Microvascular endothelium dysfunction during growth of transplanted lymphosarcoma and glioma in rats. J Exp Clin Cancer Res 18:537-542
47. Geiger M, Binder BR (1999) Pathophysiology of immobilization. Wien Med Wochenschr 149:33-34
48. Gibbs NM (1957) Venous thrombosis of the lower limbs with particular reference to bed rest. Br J Surg 45:209
49. Warlow C, Ogston D, Douglas AS (1976) Deep venous thrombosis of the legs after strokes. Part I - incidence and predisposing factors. Br Med J 1:1178-1181
50. Turpie AG, Gallus A, Beattie WS, Hirsh J (1977) Prevention of venous thrombosis in patients with intracranial disease by intermittent pneumatic compression of the calf. Neurology 27:435-438
51. Heit JA (2006) The epidemiology of venous thromboembolism in the community: Implications for prevention and management. J Thromb Thrombolysis 21:23-29
52. Cohen LF, Balow JE, Magrath IT et al (1980) Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med 68:486-491
53. Haddad TC, Greeno EW (2006) Chemotherapy-induced thrombosis. Thromb Res 118:555-568
54. Agnelli G, Verso M (2006) Therapy Insight: Venous-catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol 3:214-222
55. Pavic M, Debourdeau P, Aletti M, Farge-Bancel D, Rousset H (2006) Venous thromboembolism and cancer. Rev Med Interne 27:313-322
56. Gouin-Thibault I, Achkar A, Samama MM (2001) The thrombophilic state in cancer patients. Acta Haematol 106:33-42
57. Falanga A (2005) Thrombophilia in cancer. Semin Thromb Hemost 31:104-110
58. Oberhoff C, Rollwagen C, Tauchert AM, Hoffmann O, Winkler UH, Schindler AE (2001) Perioperative development of a thrombogenic risk profile in patients with carcinomas of the breast: A cause of increased thrombosis. Eur J Gynaecol Oncol 21:560-568
59. Tripodi A, Mannucci PM, Chantarangkul V et al (1993) Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders. Br J Haematol 84:670-674
60. Sallah S, Husain A, Sigounas V et al (2004) Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 10:7238-7243
61. Sagripanti A, Carpi A, Baicchi U, Grassi B (1993) Plasmatic parameters of fibrin formation and degradation in cancer patients: Correlation between fibrinopeptide A and D-dimer. Biomed Pharmacother 47:235-239
62. Chojnowski K, Trelinski J, Wawrzyniak E, Robak T (2002) The influence of low molecular weight heparin on the intravascular activation of the coagulation system in patients with acute leukemia during induction chemotherapy-report of a prospective randomized study. Leuk Lymphoma 43:1021-1028
63. Dixit A, Kannan M, Mahapatra M, Choudhry VP, Saxena R (2006) Roles of protein C, protein S, and antithrombin III in acute leukemia. Am J Hematol 81:171-174
64. Beer JH, Haeberli A, Vogt A et al (2002) Coagulation markers predict survival in cancer patients. Thromb Haemost 88:745-749
65. Blackwell K, Hurwitz H, Lieberman G et al (2004) Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 101:77-82
66. Kim HK, Song KS, Lee KR, Kang YH, Lee YJ, Lee ES (2004) Comparison of plasma D-dimer and thrombus precursor protein in patients with operable breast cancer as a potential predictor of lymph node metastasis. Blood Coagul Fibrinolysis 15:9-13
67. Tomimaru Y, Yano M, Takachi K et al (2006) Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg 202:139-145
68. Unsal E, Atalay F, Atikcan S, Yilmaz A (2004) Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 98:93-98
69. Paneesha S, Cheyne E, French K, Bacchu S, Borg A, Rose P (2006) High D-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes. Br J Haematol 135:85-90
70. Schutgens RE, Beckers MM, Haas FJ, Biesma DH (2005) The predictive value of D-dimer measurement for cancer in patients with deep vein thrombosis. Haematologica 90:214-219
71. Rege KP, Jones S, Day J, Hoggarth CE (2004) In proven deep vein thrombosis, a low positive D-Dimer score is a strong negative predictor for associated malignancy. Thromb Haemost 91:1219-1222
72. Agnelli G (1997) Venous thromboembolism and cancer: A two way clinical association. Thromb Haemost 78:117-120
73. Nordstrom M, Lindbald B, Anderson H et al (1994) Deep vein thrombosis and occult malignancy: An epidemiological study. Br Med J 308:891-894
74. Cornuz J, Pearson SD, Creagor MA et al (1996) Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep vein thrombosis. Ann Intern Med 25:785-793
75. Monreal M, Fernandez-Llamazares, Perandreu J, Urrutia A, Sahuquillo JC, Contel E (1997) Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 78:1316-1318
76. Hettiarachchi RJ, Lok J, Prins MH, Buller HR, Prandoni P (1998) Undiagnosed malignancy in patients with deep vein thrombosis: Incidence, risk indicators, and diagnosis. Cancer 83:180-185
77. Rajan R, Levine M, Gent M, Hirsh J, Geerts W, Skingley P, Julian J (1998) The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: Results from a historical cohort study. Thromb Haemost 79:19-22
78. Rance A, Emmerich J, Guedi C et al (1997) Occult cancer in patients with bilateral deep-vein thrombosis. Lancet 350:1448-1449
79. Sorensen HT, Mellemkjaer L, Steffensen FH et al (1998) The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338:1169-1173
80. Baron JA, Gridley G, Weiderpass E et al (1998) Venous thromboembolism and cancer. Lancet 351:1077-1080
81. Sorensen HT, Mellmkjaer L, Olsen JH et al (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846-1850
82. Prandoni P, Lensing AW, Buller HR et al (1992) Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327:1128-1133
83. Monreal M, Casal A, Boix J et al (1993) Occult cancer in patients with acute pulmonary embolism. A prospective Study Chest 103:816-819
84. Monreal M, Lensing AWA, Prins MH et al (2004) Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2:876-881
85. Piccioli A, Lensing AW, Prins MH et al, SOMIT Investigators Group. (2004) Extensive screening for occult malignant disease in idiopathic venous thromboembolism: A prospective randomized clinical trial. J Thromb Haemost 2:884-889
86. Kakkar AK (2004) Thrombosis and cancer. Hematol J 5:S20-23
87. Levine MN, Lee AY (2003) Risk assessment and primary VTE prevention in cancer patients. Pathophysiol Haemost Thromb 33(Suppl.1):36-41
88. Mousa SA (2002) Anticoagulants in thrombosis and cancer: The missing link. Semin Thromb Hemost 28:45-52
89. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H (2001) Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88:913-930
90. Levine M, Hirsh J, Gent M et al (1994) Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886-889
91. Bern MM, Lokich JJ, Wallach SR et al (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 112:423-428
92. Couban S, Simpson DR, Barnett MJ et al, Canadian Bone Marrow Transplant Group. (2002) A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 100:1525-1531
93. Mousa SA (2005) Antithrombotics in thrombosis and cancer. Hamostaseologie 25:380-386
94. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM (1999) Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130:800-809
95. van Dongen CJ, Mac Gillavry MR, Prins MH (2003) Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 1:CD003074
96. Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488
97. Lee AY, Levine MN, Baker RI et al, Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153
98. Meyer G, Marjanovic Z, Valcke J et al (2002) Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 162:1729-1735
99. Schafer AI, Levine MN, Konkle BA, Kearon C (2003) Thrombotic disorders: diagnosis and treatment. Hematology Am Soc Hematol Educ Program 520-539